Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai

Exclusion Criteria

• •1. Non-permanent residents of Shanghai who have stayed in the city for more than 30 days; or permanent residents of Shanghai who have left the city within the past 30 days.
• •2. History of significant illness or major surgery within the past 30 days, or anticipation of major surgery during the study period.
• •3. Diagnosis of respiratory diseases (infectious or non-infectious) within the past 30 days, requiring medication (oral, inhaled, or nebulized).
• •4. Presence of clinically significant diseases or factors, including but not limited to neurological, cardiovascular, hematologic, hepatic, renal, gastrointestinal, respiratory, metabolic, endocrine, immune, skeletal diseases, or other conditions deemed unsuitable by the investigator.
• •5. Long-term use of medication.
• •6. Positive test results for HIV antibodies (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C antibodies (HCV-Ab), or syphilis antibodies (TP-Ab).
• •7. Participation in any drug or medical device clinical trial within the past 3 months.
• •8. Vaccination within the past 30 days or planned vaccination during the study period.
• •9. Any other condition deemed by the investigator to impact the participant's ability to provide informed consent, follow the protocol, or affect study outcomes or the participant's safety.
• •2\. Elderly Healthy Volunteers
• •1. Non-permanent residents of Shanghai who have stayed in the city for more than 30 days; or permanent residents of Shanghai who have left the city within the past 30 days.
• •2. History of significant illness or major surgery within the past 30 days, or anticipation of major surgery during the study period.
• •3. Diagnosis of respiratory diseases (infectious or non-infectious) within the past 30 days, requiring medication (oral, inhaled, or nebulized).
• •4. Presence of abnormal respiratory system function or other clinically significant diseases or conditions.
• •5. History of malignant tumors (including hematologic malignancies or solid tumors).
• •6. Long-term use of medication.
• •7. Positive test results for HIV antibodies (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C antibodies (HCV-Ab), or syphilis antibodies (TP-Ab).
• •8. Participation in any drug or medical device clinical trial within the past 3 months.
• •9. Vaccination within the past 30 days or planned vaccination during the study period.
• •10. Any other condition deemed by the investigator to impact the participant's ability to provide informed consent, follow the protocol, or affect study outcomes or the participant's safety.